Combined immunosuppression impairs immunogenicity to tetanus and pertussis vaccination among patients with inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 21, Issue 8, 2015, Pages 1754-1760

  Dezfoli, Seper ^a   Horton, Henry A ^a   Thepyasuwan, Nattapaun ^a   Berel, Dror ^a   Targan, Stephan R ^a   Vasiliauskas, Eric A ^a   Dubinsky, Marla ^a   Shih, David Q ^a   Kaur, Manreet ^a   McGovern, Dermot P B ^a   Ippoliti, Andrew ^a   Feldman, Edward J ^a   Melmed, Gil Y ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Anti tumor necrosis factor alpha; Crohn disease; Inflammatory bowel disease; Pertussis; Tetanus; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; DIPHTHERIA PERTUSSIS TETANUS VACCINE; FILAMENTOUS HEMAGGLUTININ; HEMAGGLUTININ; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; TETANUS TOXOID; TOXOID; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BIOLOGICAL THERAPY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY BOWEL DISEASE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PERTUSSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; TETANUS; TETANUS PROPHYLAXIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VACCINATION; ADOLESCENT; ANTIBODY PRODUCTION; BLOOD; CASE CONTROL STUDY; CHEMICALLY INDUCED; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED; PROGNOSIS;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; TETANUS; VACCINATION; WHOOPING COUGH;

EID: 84946924027     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000448     Document Type: Article

References (36)

1. Melmed GY, Targan SR. Future biologic targets for IBD: potentials and pitfalls. Nat Rev Gastroenterol Hepatol. 2010;7:110-117.
2. Herrinton LJ, Liu L, Fireman B, et al. Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005. Gastroenterology. 2009;137:502-511.
3. Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis. 2010;4:63-101.
4. Baumgart DC, Sandborn WJ. Crohn's disease. Lancet. 2012;380:1590-1605.
5. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis. 2010;4:28-62.
6. Sands BE, Siegel CA. Crohn's disease. In: Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 9th ed. Philadelphia, PA: Saunders Elsevier; 2010:chap 111.
7. Stenson WF, Hanauer SB, Cohen RD. Inflammatory bowel disease. In: Yamada T, ed. Textbook of Gastroenterology. Oxford, United Kingdom: Blackwell Publishing Ltd.; 2009.
8. D'Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011;106:199-212. quiz 213.
9. Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006;101:1834-1840.
10. Toruner M, Loftus EV, Jr., Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929-936.
11. Viget N, Vernier-Massouille G, Salmon-Ceron D, et al. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut. 2008;57:549-558.
12. Ostuni P, Botsios C, Punzi L, et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis. 2003;62:686-687.
13. Lemyze M, Tavernier JY, Chevalon B, et al. Severe varicella zoster pneumonia during the course of treatment with azathioprine for Crohn's disease [in French]. Rev Mal Respir. 2003;20:773-776.
14. Deutsch DE, Olson AD, Kraker S, et al. Overwhelming varicella pneumonia in a patient with Crohn's disease treated with 6-mercaptopurine. J Pediatr Gastroenterol Nutr. 1995;20:351-353.
15. Foster KJ, Devitt N, Gallagher PJ, et al. Overwhelming pneumococcal septicaemia in a patient with ulcerative colitis and splenic atrophy. Gut. 1982;23:630-632.
16. Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:1483-1490.
17. Long MD, Martin C, Sandler RS, et al. Increased risk of pneumonia among patients with inflammatory bowel disease. Am J Gastroenterol. 2013;108:240-248.
18. Long MD, Farraye FA, Okafor PN, et al. Increased risk of pneumocystis jiroveci pneumonia among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:1018-1024.
19. National Center for Immunization and Respiratory Diseases. General recommendations on immunization - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60:1-64.
20. Sands BE, Cuffari C, Katz J, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:677-692.
21. Melmed GY. Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. Inflamm Bowel Dis. 2009;15:1410-1416.
22. California Department of Public Health, Immunization Branch. Pertussis Report. Available at: http://www.cdph.ca.gov/programs/immunize/Documents/Pertussis-Report-6-10-2014.pdf. Accessed April 20, 2015.
23. Halperin SA, McNeil S, Langley J, et al. Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4-5 years after a previous dose. Vaccine. 2011;29:8459-8465.
24. Blatter M, Friedland LR, Weston WM, et al. Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of age. Vaccine. 2009;27:765-772.
25. Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep. 2011;60:13-15.
26. Lu Y, Jacobson DL, Ashworth LA, et al. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol. 2009.
27. Melmed GY, Agarwal N, Frenck RW, et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:148-154.
28. Fiorino G, Naccarato P, Szabo H, et al. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2012;18:1042-1047.
29. Dotan I, Werner L, Vigodman S, et al. Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines. Inflamm Bowel Dis. 2012;18:261-268.
30. Mamula P, Markowitz JE, Piccoli DA, et al. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:851-856.
31. Brogan MD, Shanahan F, Oliver M, et al. Defective memory B cell formation in patients with inflammatory bowel disease following tetanus toxoid booster immunization. J Clin Lab Immunol. 1987;24:69-74.
32. Nielsen HJ, Mortensen T, Holten-Andersen M, et al. Increased levels of specific leukocyte- and platelet-derived substances during normal anti-tetanus antibody synthesis in patients with inactive Crohn disease. Scand J Gastroenterol. 2001;36:265-269.
33. Brogan MD, Hiserodt J, Oliver M, et al. The effect of 6-mercaptopurine on natural killer-cell activities in Crohn's disease. J Clin Immunol. 1985;5:204-211.
34. Akamatsu T, Inui N, Kusagaya H, et al. Evaluation of antibody levels over 3 years after 23-valent pneumococcal polysaccharide vaccination in patients with pulmonary diseases receiving steroids and immunosuppressive agents. Clin Biochem. 2014. pii: S0009-9120(14) 00747-754.
35. Steentoft J, Konradsen HB, Hilskov J, et al. Response to pneumococcal vaccine in chronic obstructive lung disease - the effect of ongoing, systemic steroid treatment. Vaccine. 2006;24:1408-1412.
36. Kapetanovic MC, Saxne T, Sjoholm A, et al. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford). 2006;45:106-111.